Staff Members - Benha University
Melanocortin Receptor Agonist (Corticotrophin) in Treatment of Refractory Diabetic nephropathy
• 2022
Publication Information
Authors
1
S.S.El-sayed, 1A.E.Mansour, 1A.T.Mahmoud, 1H.G.Abdelsalam, 1
S.B.Hannalla, 1E.L.El-Shahawy
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
The points of this examination are To evaluate the reaction and adequacy of melanocortin
receptor agonist (ACTH) as a treatment for patients with stubborn diabetic nephropathy . This
examination was performed on 50 diabetic patients who went to inner medication division at banha
college emergency clinic. Patients with diabetic nephropathy gave proteinuria more than 1gm/24hour
pee assortment and who are not reacting to against proteinuric measures for at any rate one month of
treatment rewarded with engineered ACTH permitting a 6 months development. Result. The essential
endpoint was the level of patients accomplishing a total reduction (
receptor agonist (ACTH) as a treatment for patients with stubborn diabetic nephropathy . This
examination was performed on 50 diabetic patients who went to inner medication division at banha
college emergency clinic. Patients with diabetic nephropathy gave proteinuria more than 1gm/24hour
pee assortment and who are not reacting to against proteinuric measures for at any rate one month of
treatment rewarded with engineered ACTH permitting a 6 months development. Result. The essential
endpoint was the level of patients accomplishing a total reduction (